[A comparative study between different regimens for administering 2 doses of the Cuban anti-hepatitis B vaccine].
A controlled clinical trial, corresponding to stage 2, was conducted in a population of sound adult males aged 18-23 to evaluate the immunogenicity of 5 schedules of Cuban vaccine against hepatitis B (Heberbiovac-HB [correction of Cheberbiovac-HB]). 5 groups were studied: I (control group 0, 1 and 6 months), II (0 and 2 months), III (0 and 4 months), IV (0 and 6 months), and V (0 and 8 months). The results showed no significant differences as regards the percentage of seroprotection of any of the groups of 2 doses compared with the control of 3 doses. It is concluded that between the first and the second dose there may be a period of time from 2 to 6 months with no need to reinitiate the schedule. This information will serve as a basis for a population based study to determine which schedule is the best to be used.
González-Griego
M de J
Mde J
Centro de Ingeniería Genética y Biotecnología, Ciudad de La Habana, Cuba.
Cinza
Z
Z
Ortega
A
A
Gali
M M
MM
Santoyo
M E
ME
García
G
G
Delahanty
A
A
D000293:Adolescent; D000328:Adult; D003462:Cuba; D004306:Dose-Response Relationship, Immunologic; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D013997:Time Factors; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D019444:Vaccines, DNA; C115360:heberbiovac-HB